Spica Healthcare β€” Unit of Grover Hospital, Bathinda
HomeHealth Guides & BlogsMedical Oncology & ChemotherapyHepatocellular Carcinoma (HCC): Atezolizumab + Bevacizumab vs. TKI (Lenvatinib/Sorafenib) in Intermediate and Advanced Staging
Medical Oncology & Chemotherapy

Hepatocellular Carcinoma (HCC): Atezolizumab + Bevacizumab vs. TKI (Lenvatinib/Sorafenib) in Intermediate and Advanced Staging

11 min read
Sep 2, 2026
Spica Healthcare Clinical & Surgical Protocol Illustration #103

Clinical Summary & Key Takeaways

A clinical oncology update on managing primary liver cancer (HCC), detailing BCLC staging, IMbrave150 immunotherapy (Atezolizumab + Bevacizumab), anti-VEGF management of variceal bleeding, tyrosine kinase inhibitors (Lenvatinib, Cabozantinib), and liver resection thresholds.

CRITICAL CLINICAL RED FLAG: Patients with known chronic hepatitis B/C or cirrhosis who develop dull right upper quadrant abdominal fullness, unprovoked ascites, or rapid elevation of serum Alpha-Fetoprotein (AFP) require immediate multiphasic liver CECT or Primovist MRI.

1. The Modern Staging Framework: BCLC Classification & Child-Pugh Score

Hepatocellular Carcinoma arises in the setting of chronic hepatic fibrosis and cirrhosis in >80% of cases. Treatment choice is dictated by liver functional reserve (Child-Pugh Score A vs B) alongside the Barcelona Clinic Liver Cancer (BCLC) algorithm.

  • BCLC 0/A (Early Stage): Solitary nodule <=5 cm or <=3 nodules <=3 cm with preserved Child-Pugh A β€” candidates for radical surgical resection or microwave ablation.

  • BCLC B (Intermediate Stage): Multinodular asymptomatic disease without vascular invasion β€” managed with Transarterial Chemoembolization (TACE) or systemic therapy.

  • BCLC C (Advanced Stage): Portal vein invasion or extrahepatic spread β€” candidates for frontline systemic immunotherapy.

2. Frontline Systemic Regimens: The IMbrave150 Benchmark

The phase III IMbrave150 trial supplanted multi-kinase inhibitors (Sorafenib) as frontline therapy:

  1. Atezolizumab (anti-PD-L1) + Bevacizumab (anti-VEGF): Achieved an overall survival exceeding 19.2 months with an objective response rate of 30%.

  2. Durvalumab + Tremelimumab (STRIDE Regimen - HIMALAYA Trial): Dual checkpoint blockade offering a non-VEGF frontline alternative for patients with high bleeding risk.

  3. Lenvatinib: An effective oral TKI alternative demonstrating non-inferior overall survival and high tumor shrinkage rates.

"The combination of immune checkpoint inhibition and anti-angiogenesis has doubled median overall survival in advanced liver cancer, transforming a historically lethal disease." β€” Dr. Neha Gupta
Spica Healthcare Clinical & Surgical Protocol Illustration #103
Spica Healthcare Clinical & Surgical Protocol Illustration #103

3. Managing VEGF-Related Toxicities: Hypertension & Proteinuria

Rigorous home blood pressure monitoring (target <140/90 mmHg) and routine urine dipstick analysis for proteinuria (grade >=2 requiring dose interruption) are essential components of safe outpatient delivery.

CLINICAL CAUTION: Upper GI endoscopy must be performed within 6 months prior to initiating Bevacizumab in HCC patients to treat high-risk esophageal varices and avoid catastrophic gastrointestinal bleeding.

4. Second-Line Sequential Therapy Options

For patients with progressive disease post-immunotherapy, second-line options include Cabozantinib, Regorafenib (for prior sorafenib responders), and Ramucirumab (for patients with baseline AFP >=400 ng/mL).

5. Peer-Reviewed References & Clinical Guidelines

1. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma (IMbrave150) β€” NEJM, 2020; 382: 1894-1905.

2. Tremelimumab plus Durvalumab in Advanced Hepatocellular Carcinoma (HIMALAYA Trial) β€” Lancet Oncol, 2022; 23(10): 1310-1323.

Frequently Asked Patient Questions

Limb Salvage with modular titanium megaprosthesis removes the tumor completely while preserving the limb, allowing patients to walk, work, and maintain full social independence without the physical disability of an artificial limb.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Senior Consultant & Clinical Director β€” Medical Oncology

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Share this medical guide:
WhatsApp
Director-Led Clinical Breakthroughs

Signature Surgical Innovations & Techniques

Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

1 of 13
Comprehensive Bone Cancer Oncology & Limb Preservation
Click to Watch Video Demonstration
95%+ Limb Salvage & MAP Chemotherapy
Multidisciplinary Limb Salvage, MAP Chemotherapy & Modular Megaprosthetics

Comprehensive Bone Cancer Oncology & Limb Preservation

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.

Key Advantages Over Conventional Surgery:
Coordinated Surgical & Medical Oncology: Seamless dual leadership under Dr. Deepak Garg & Dr. Neha Gupta
95%+ Limb Preservation Rate: Wide oncological bone resection avoiding traumatic limb amputations
High-Grade Sarcoma Chemotherapy: Standardized MAP and VIDE protocols delivering high tumor necrosis rates (>90%)
Custom Modular Megaprostheses: Immediate joint restoration with biological tendon ingrowth collars
Why Families & Physicians Trust Spica

World-Class Clinical Precision, Built on Compassion

Spica Healthcare β€” Bone and Cancer Institute, Bathinda β€” is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.

AIIMS & Tata Memorial Alumni25+ Yrs Combined Senior Leadership

15,000+ Complex Surgeries & 100% Director-Led Evaluations

Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists β€” Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) β€” guaranteeing zero junior proxies.

15,000+Surgeries Completed
95%+Limb Salvage Rate
<0.3%Infection Benchmark
Pre-Op 3D Virtual Planning 100% Direct Director OPD Day-1 Walking Protocol
Sub-Millimeter Accuracy

3D Navigated Robotics & Day-1 Walking

Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.

ROSA Robotics & Stryker Nav
Malwa Punjab Exclusive

Limb-Salvage Over Amputation

South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.

Modular Megaprosthesis
0-Out-Of-Pocket Options

100% Cashless PM-JAY & TPAs

Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.

Ayushman + 30+ TPAs Empanelled
24/7 Tertiary Ready

Class-100 Laminar Flow OTs & ICU

Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.

Spica Healthcare Bathinda
Expert Surgical Directors

Meet the Doctors at Spica Healthcare

Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Dr. Neha Gupta

Senior Consultant & Clinical Director β€” Medical Oncology

13+ Yrs Exp

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Medical Oncology & ChemotherapyImmunotherapy & Targeted OncologyPrecision Oncology & Cancer GenomicsPreventive Cancer ScreeningPalliative & Supportive OncologyHormonal TherapyComprehensive Cancer Treatments
Dr. Deepak Garg - Director & Senior Joint Replacement, Spine and Orthopaedic Oncologist

Dr. Deepak Garg

Senior Consultant & Clinical Director β€” Orthopaedic Oncology & Robotic Joint Surgery

16+ Yrs Exp

MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)

Orthopaedic Oncology & Bone Tumors3D Robotic Joint ReplacementSports Injuries & ArthroscopyTrauma & Fracture ReconstructionGeneral Orthopaedics & Spine CareComprehensive Cancer Treatments
Community Health & Academic Outreach

Upcoming Health Camps & Academic Events

Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.

Curious what families & patients experience

Hear what our patients are saying

Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare β€” Grover Hospital, Bathinda.

Health Knowledge & Clinical Guides

Doctor-Authored Health Guides

Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.